Literature DB >> 5301791

[Malignant melanoblastoma of the uvea. Results of a comparative study of tissue cultures].

O E Lung, G Kersting.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5301791     DOI: 10.1007/bf00406588

Source DB:  PubMed          Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol        ISSN: 0065-6100


× No keyword cloud information.
  13 in total

1.  [CONTRIBUTION TO THE STUDY OF MELANOTIC TUMORS OF THE UVEA AND THEIR ORIGIN].

Authors: 
Journal:  Doc Ophthalmol       Date:  1963       Impact factor: 2.379

2.  ELECTRON MICROSCOPY OF MELANOMAS OF THE HUMAN UVEAL TRACT: THE ULTRASTRUCTURE OF FOUR MALIGNANT MELANOMAS OF THE MIXED CELL TYPE.

Authors:  F BIERRING; O A JENSEN
Journal:  Acta Ophthalmol (Copenh)       Date:  1964

3.  In vitro behaviour of the pigmented cells of the retina and uvea of the adult human eye.

Authors:  Y R BARISHAK
Journal:  Acta Ophthalmol (Copenh)       Date:  1960

4.  Ultrastructure of malignant melanomas of the choroid.

Authors:  M J HOGAN; L FEENEY
Journal:  Invest Ophthalmol       Date:  1962-08

5.  The culture of uveal melanomas; the Proctor Medal lecture.

Authors:  A B REESE; G EHRLICH
Journal:  Am J Ophthalmol       Date:  1958-11       Impact factor: 5.258

6.  Tumors of the retinal pigment epithelium.

Authors:  J R FAIR
Journal:  Am J Ophthalmol       Date:  1958-04       Impact factor: 5.258

7.  Malignant melanoma of the choroid and ciliary body; a study of 2,535 cases.

Authors:  H C WILDER; E V PAUL
Journal:  Mil Surg       Date:  1951-10

8.  THE ORIGIN OF THE MALIGNANT MELANOMATA.

Authors:  E Wolff
Journal:  Br J Ophthalmol       Date:  1948-02       Impact factor: 4.638

9.  Four cases of human choroid melanoblastoma cultured in vitro.

Authors:  F VRABEC
Journal:  Ophthalmologica       Date:  1948-03       Impact factor: 3.250

10.  [Sarcomas of the choroid; aspect, nature and origin].

Authors:  J NORDMANN; A BRINI
Journal:  Doc Ophthalmol       Date:  1951       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.